Description
Jakavi 15 mg contains Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor designed to block abnormal signaling pathways responsible for excessive blood cell production and inflammatory cytokine release. It is widely used in hematology for managing chronic myeloproliferative diseases.
🔬 Mechanism of Action
Ruxolitinib inhibits the JAK-STAT signaling pathway, which plays a key role in hematopoiesis and immune regulation. By suppressing overactive JAK signaling, it:
- Reduces abnormal blood cell proliferation
- Decreases inflammatory cytokine activity
- Shrinks enlarged spleen (splenomegaly)
- Relieves symptoms such as fatigue, fever, night sweats, and bone pain
💊 Indications
Jakavi 15 mg is indicated for:
- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
- Polycythemia Vera (PV) in patients resistant or intolerant to hydroxyurea
- Acute or Chronic Graft-versus-Host Disease (GVHD)
📌 Key Features of Jakavi 15 mg
- Strength: 15 mg
- Dosage Form: Oral tablet
- Therapeutic Class: JAK1/JAK2 Inhibitor
- Administration: Taken orally, dose adjusted based on platelet count and medical condition
- Monitoring: Regular complete blood counts (CBC) and liver function tests required
⚕️ Benefits of Ruxolitinib
- Effective symptom control in myelofibrosis
- Reduces spleen size
- Improves overall survival in certain patients
- Oral therapy for convenient dosing
⚠️ Precautions
- Risk of anemia and thrombocytopenia
- Increased susceptibility to infections
- Dose adjustments may be necessary based on blood counts
- Regular monitoring essential during therapy
- Use strictly under hematologist supervision
Jakavi 15 mg (Ruxolitinib Tablets) provides a targeted treatment option for myeloproliferative disorders and GVHD, helping manage disease symptoms and improve patient outcomes when administered under specialized medical care.
